Related Experiment Video
Updated: Aug 3, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 19, 2013
Monoclonal antibody specific for human T acute lymphoblastic leukaemia
Abstract:
A cytotoxic mouse monoclonal antibody (CALL2) was produced against a cultured T acute lymphocytic leukaemia (T ALL) cell line 8402. Ascites fluid containing the antibody was cytotoxic to a titre of up to 1:100 000 against 4 of 6 cultured T ALL cell lines and against leukaemia cells from 7 of 8 T ALL patients and 1 of 5 T chronic lymphatic leukaemia patients. The antibody did not react with normal peripheral-blood T and B lymphocytes, monocytes, granulocytes, spleen cells, thymocytes, platelets, and other acute and chronic leukaemia cells. The CALL2 antibody did not react with bone marrow stem cells of the myeloid series (CFU-C). This antibody may be useful for passive immunotherapy trials since it does not react with normal cells and is highly cytotoxic to T ALL cells.
More Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
08:31Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025